Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sufentanil · Dsuvia, Sufenta Preservative Free

Small molecule · developed by Rising

Approved FDA, May 1984
5 Registered trials

What is Sufentanil?

Sufentanil is an intravenous and sublingual formulation studied for acute moderate-to-severe pain, including postoperative pain after major upper or lower abdominal surgery.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Dsuvia, Sufenta Preservative Free, ST 30
Drug type
Small molecule
Therapy area
Oncology
Developer
Rising
In trials of
TLPH
FDA status
Approved as Dsuvia, Sufenta Preservative Free (May 4, 1984), NDA019050
UNII
AFE2YW0IIZ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02662556 Phase 3 Acute Moderate-to-severe Pain Completed TLPH
NCT02447848 Phase 3 Moderate-to-severe Acute Pain Completed TLPH
NCT02356588 Phase 3 Post-Operative Pain Completed TLPH
NCT00718081 Phase 2 Major Upper or Lower Abdominal Surgery Completed TLPH
NCT01639729 Phase 1 Pharmacokinetics Completed TLPH

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Moderate-to-severe PainMajor Upper or Lower Abdominal SurgeryModerate-to-severe Acute PainPharmacokineticsPost-Operative Pain

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.